Quest Diagnostics director adds shares via DRIP

Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition.

Rhea-AI Filing Summary

Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.

Insider Trade Summary

Small Acquisition: 67 shares

Small Acquisition 1 txn

Insider Gregg Vicky B

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	67	$183.513	$12K

Holdings After Transaction: Common Stock — 17,104 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) disclose for Vicky B. Gregg?

Quest Diagnostics director Vicky B. Gregg reported acquiring 67 shares of common stock via a dividend reinvestment plan at $183.513 per share. This routine transaction slightly increased her direct ownership and was voluntarily reported early on Form 4.

How many Quest Diagnostics (DGX) shares does Vicky B. Gregg now own?

After the reported transaction, Vicky B. Gregg directly owns 17,104 shares of Quest Diagnostics common stock. This total reflects the addition of 67 shares acquired through a broker-administered dividend reinvestment plan on January 28, 2026.

What was the price per share in the latest Quest Diagnostics (DGX) insider acquisition?

The reported acquisition by director Vicky B. Gregg was priced at $183.513 per Quest Diagnostics common share. The 67 shares were obtained automatically through a dividend reinvestment plan rather than a discretionary open-market purchase.

How was the Quest Diagnostics (DGX) insider transaction executed for Vicky B. Gregg?

The transaction was executed through a dividend reinvestment plan administered by the director’s broker. Dividends were automatically used to acquire 67 additional Quest Diagnostics shares, increasing her direct holdings without a separate open-market trade.

Why was the Quest Diagnostics (DGX) insider transaction reported on Form 4 instead of Form 5?

The dividend reinvestment transaction was eligible for deferred reporting on Form 5 under SEC Rule 16a-6, but the reporting person chose to disclose it early on Form 4, providing more timely transparency about the incremental share acquisition.

Does the Quest Diagnostics (DGX) filing indicate a buy or sell by Vicky B. Gregg?

The filing indicates an acquisition, not a sale. Director Vicky B. Gregg received 67 additional Quest Diagnostics shares through a dividend reinvestment plan, increasing her direct ownership to 17,104 shares following the automatic transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:06 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gregg Vicky B

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		L	V	67(1)	A	$183.513	17,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Vicky B. Gregg	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.